Yeungnam Univ J Med.  2006 Dec;23(2):143-151. 10.12701/yujm.2006.23.2.143.

Target Therapy for Colorectal Cancer

• Lee KH

• KMID: 2049770
• DOI: http://doi.org/10.12701/yujm.2006.23.2.143

Abstract

In the past decade, the median duration of survival among patients with advanced colorectal cancer has increased from 12 months to about 18 months, primarily as a results of the introduction of irinotecan and oxaliplatin. Advances in the understanding of the molecular mechanisms underlying the development and progression of cancer have resulted in the discovery of new therapeutic interventions that target specific molecular abnormalities. Their specificity, and therefore their potential to bind preferentially and modify tumor-specific targets, sparing normal tissues and causing fewer side-effects compared to conventional cytotoxic agents, makes them an attractive therapeutic option. The future of this approach for the treatment of solid tumors is promising

Keyword

Target therapy; Colorectal cancer

MeSH Terms

Colorectal Neoplasms*
Cytotoxins
Humans
Cytotoxins